Literature DB >> 27881849

Are diuretic additives fit for uncontrolled hypertensive patients receiving telmisartan and amlodipine treatment?

Yoshiaki Taniyama1, Ryuichi Morishita1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27881849     DOI： 10.1038/hr.2016.154

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  9 in total

1.  Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.

Authors:  Hiromi Rakugi; Takuya Tsuchihashi; Kazuyuki Shimada; Hirotaka Numaguchi; Chisato Nishida; Hiroya Yamaguchi; Masayoshi Shirakawa; Kyoichi Azuma; Kenji P Fujita
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014).

Authors:  Kazuaki Shimamoto; Katsuyuki Ando; Toshiro Fujita; Naoyuki Hasebe; Jitsuo Higaki; Masatsugu Horiuchi; Yutaka Imai; Tsutomu Imaizumi; Toshihiko Ishimitsu; Masaaki Ito; Sadayoshi Ito; Hiroshi Itoh; Hiroshi Iwao; Hisashi Kai; Kazuomi Kario; Naoki Kashihara; Yuhei Kawano; Shokei Kim-Mitsuyama; Genjiro Kimura; Katsuhiko Kohara; Issei Komuro; Hiroo Kumagai; Hideo Matsuura; Katsuyuki Miura; Ryuichi Morishita; Mitsuhide Naruse; Koichi Node; Yusuke Ohya; Hiromi Rakugi; Ikuo Saito; Shigeyuki Saitoh; Kazuyuki Shimada; Tatsuo Shimosawa; Hiromichi Suzuki; Kouichi Tamura; Norio Tanahashi; Takuya Tsuchihashi; Makoto Uchiyama; Shinichiro Ueda; Satoshi Umemura
Journal:  Hypertens Res       Date:  2014-04       Impact factor: 3.872

Review 4.  Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk.

Authors:  Sebastiano Sciarretta; Francesca Palano; Giuliano Tocci; Rossella Baldini; Massimo Volpe
Journal:  Arch Intern Med       Date:  2010-11-08

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

6.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

7.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

8.  Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability.

Authors:  Takao Saruta; Toshio Ogihara; Ikuo Saito; Hiromi Rakugi; Kazuaki Shimamoto; Hiroaki Matsuoka; Satoshi Teramukai; Jitsuo Higaki; Sadayoshi Ito; Kazuyuki Shimada
Journal:  Hypertens Res       Date:  2014-09-25       Impact factor: 3.872

9.  The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.

Authors:  Jitsuo Higaki; Issei Komuro; Kosuke Shiki; Hiroyuki Ugai; Atsushi Taniguchi; Hiroshi Ikeda; Daisuke Kuroki; Seiichiro Nishimura; Toshio Ogihara
Journal:  Hypertens Res       Date:  2016-09-01       Impact factor: 3.872
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.